Approval of the first U.S. transcatheter aortic heart valve came slightly later than Edwards Lifesciences anticipated, but Sapien will reach the market just in time for a highly anticipated debut at the Transcatheter Cardiovascular Therapeutics annual meeting in San Francisco this week.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?